{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:27Z","timestamp":1791304347373,"version":"4.3.1"},"reference-count":55,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:00:00Z","timestamp":1592092800000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2020,5,13]]},"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Fas\/Fas ligand (FasL) and B cell-activating factor (BAFF) signalling have pivotal roles in SLE pathogenesis. We investigated the clinical associations of serum concentrations of soluble Fas (sFas) and soluble FasL (sFasL) in SLE and their relationship with BAFF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum sFas and sFasL were quantified by multiplex assay, and BAFF by ELISA, in 118 patients with SLE and 17 healthy controls (HC). SLE disease activity and organ damage were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics Damage Index.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>sFas, sFasL and BAFF were detectable in all samples. Serum sFas and sFasL were significantly higher in SLE compared with HC. In univariable regression analyses, patients with active renal disease and those with flare had significantly higher levels of sFas compared with those without. High serum BAFF in patients with SLE was associated with increased sFas but not sFasL. The association between sFas and renal disease remained significant after adjusting for BAFF, but the association with flare attenuated. High sFas levels were associated with increased time-adjusted mean SLEDAI-2K, even after adjusting for BAFF, and with higher odds of flare over time. In contrast, high sFasL was associated with reduced organ damage over time. Serum sFasL\/sFas ratio was negatively associated with active overall disease, flare and organ damage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Serum sFas is associated with active renal SLE, and active disease and flare over time, while sFasL\/sFas ratio is negatively associated with disease activity and organ damage accrual. Treatments correcting abnormal levels of sFas\/FasL may be worthy of evaluation in SLE.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2019-000375","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T05:47:05Z","timestamp":1592286425000},"page":"e000375","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-0800","authenticated-orcid":false,"given":"Fabien B","family":"Vincent","sequence":"first","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rangi","family":"Kandane-Rathnayake","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Koelmeyer","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harris","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9416-7383","authenticated-orcid":false,"given":"Alberta Y","family":"Hoi","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Mackay","sequence":"additional","affiliation":[{"name":"Department of Immunology and Pathology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia"},{"name":"Department of Microbiology and Immunology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"2025091512012723000_7.1.e000375.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60128-8"},{"key":"2025091512012723000_7.1.e000375.2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1590\/S1807-59322010000300014","article-title":"The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus","volume":"65","author":"Liphaus","year":"2010","journal-title":"Clinics"},{"key":"2025091512012723000_7.1.e000375.3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.smim.2014.06.001","article-title":"Roles of ligands from the TNF superfamily in B cell development, function, and regulation","volume":"26","author":"Figgett","year":"2014","journal-title":"Semin Immunol"},{"key":"2025091512012723000_7.1.e000375.4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.09.040191.001331"},{"key":"2025091512012723000_7.1.e000375.5","doi-asserted-by":"publisher","DOI":"10.1038\/356314a0"},{"key":"2025091512012723000_7.1.e000375.6","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90375-1"},{"key":"2025091512012723000_7.1.e000375.7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/107999003322277856","article-title":"Lack of proapoptotic activity of soluble CD95 ligand is due to its failure to induce CD95 oligomers","volume":"23","author":"Jang","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"2025091512012723000_7.1.e000375.8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.12.2045"},{"key":"2025091512012723000_7.1.e000375.9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.7.1209"},{"key":"2025091512012723000_7.1.e000375.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.7510905"},{"key":"2025091512012723000_7.1.e000375.11","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.4049\/jimmunol.154.6.2706","article-title":"Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing","volume":"154","author":"Cascino","year":"1995","journal-title":"J Immunol"},{"key":"2025091512012723000_7.1.e000375.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature08402"},{"key":"2025091512012723000_7.1.e000375.13","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.334"},{"key":"2025091512012723000_7.1.e000375.14","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1002\/art.38806","article-title":"Distinct effects of soluble and membrane-bound Fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients","volume":"66","author":"Audo","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091512012723000_7.1.e000375.15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M305896200"},{"key":"2025091512012723000_7.1.e000375.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.10.003"},{"key":"2025091512012723000_7.1.e000375.17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00403-005-0616-2","article-title":"Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese","volume":"297","author":"Hao","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"2025091512012723000_7.1.e000375.18","first-page":"135","article-title":"Correlation between serum levels of soluble Fas (CD95\/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran","volume":"13","author":"Sahebari","year":"2010","journal-title":"Arch Iran Med"},{"key":"2025091512012723000_7.1.e000375.19","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828145"},{"key":"2025091512012723000_7.1.e000375.20","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/780406","article-title":"Soluble Fas and the -670 polymorphism of Fas in lupus nephritis","volume":"2014","author":"Bollain-Y-Goytia","year":"2014","journal-title":"Int J Nephrol"},{"key":"2025091512012723000_7.1.e000375.21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.archger.2009.09.032","article-title":"Serum sFas\/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age","volume":"49","author":"Turi","year":"2009","journal-title":"Arch Gerontol Geriatr"},{"key":"2025091512012723000_7.1.e000375.22","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-901.x"},{"key":"2025091512012723000_7.1.e000375.23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/08820130903401736","article-title":"Fas gene polymorphisms in systemic lupus erythematosus and serum levels of some apoptosis-related molecules","volume":"39","author":"Araste","year":"2010","journal-title":"Immunol Invest"},{"key":"2025091512012723000_7.1.e000375.24","doi-asserted-by":"publisher","DOI":"10.1191\/096120399678840765"},{"key":"2025091512012723000_7.1.e000375.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.3.237"},{"key":"2025091512012723000_7.1.e000375.26","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn142"},{"key":"2025091512012723000_7.1.e000375.27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1346-8138.1998.tb02402.x","article-title":"Membranous and soluble forms of Fas antigen in cutaneous lupus erythematosus","volume":"25","author":"Fushimi","year":"1998","journal-title":"J Dermatol"},{"key":"2025091512012723000_7.1.e000375.28","first-page":"83","article-title":"Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus","volume":"38","author":"Alecu","year":"2000","journal-title":"Rom J Intern Med"},{"key":"2025091512012723000_7.1.e000375.29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001090"},{"key":"2025091512012723000_7.1.e000375.30","doi-asserted-by":"publisher","DOI":"10.1007\/s100670170023"},{"key":"2025091512012723000_7.1.e000375.31","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-04-2119","article-title":"Fas\/Fas ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer","volume":"11","author":"Nadal","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025091512012723000_7.1.e000375.32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2015.12.022","article-title":"Soluble Fas\/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease","volume":"79","author":"Adly","year":"2016","journal-title":"Cytokine"},{"key":"2025091512012723000_7.1.e000375.33","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10495-011-0604-2","article-title":"Matrix metalloproteinases and soluble Fas\/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis","volume":"16","author":"Musia\u0142","year":"2011","journal-title":"Apoptosis"},{"key":"2025091512012723000_7.1.e000375.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0803-1"},{"key":"2025091512012723000_7.1.e000375.35","first-page":"254","article-title":"Serum soluble Fas and Fas ligand (FasL) in primary Sj\u00f6gren's syndrome","volume":"37 Suppl 118","author":"Vincent","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025091512012723000_7.1.e000375.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.33"},{"key":"2025091512012723000_7.1.e000375.37","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1996.290"},{"key":"2025091512012723000_7.1.e000375.38","doi-asserted-by":"publisher","DOI":"10.1038\/35010115"},{"key":"2025091512012723000_7.1.e000375.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.05.019"},{"key":"2025091512012723000_7.1.e000375.40","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/art.38573","article-title":"Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare","volume":"66","author":"Munroe","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025091512012723000_7.1.e000375.41","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025091512012723000_7.1.e000375.42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu153"},{"key":"2025091512012723000_7.1.e000375.43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207726"},{"key":"2025091512012723000_7.1.e000375.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01250","article-title":"Analysis of Serum Interleukin (IL)-1\u03b2 and IL-18 in Systemic Lupus Erythematosus","volume":"9","author":"Mende","year":"2018","journal-title":"Front Immunol"},{"key":"2025091512012723000_7.1.e000375.45","first-page":"824","article-title":"Adjusted mean systemic lupus erythematosus disease activity Index-2K is a predictor of outcome in SLE","volume":"32","author":"Iba\u00f1ez","year":"2005","journal-title":"J Rheumatol"},{"key":"2025091512012723000_7.1.e000375.46","first-page":"1977","article-title":"Summarizing disease features over time: I. adjusted mean SLEDAI derivation and application to an index of disease activity in lupus","volume":"30","author":"Iba\u00f1ez","year":"2003","journal-title":"J Rheumatol"},{"key":"2025091512012723000_7.1.e000375.47","doi-asserted-by":"crossref","DOI":"10.1038\/srep34604","article-title":"Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus","volume":"6","author":"Godsell","year":"2016","journal-title":"Sci Rep"},{"key":"2025091512012723000_7.1.e000375.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2025091512012723000_7.1.e000375.49","first-page":"373","article-title":"The systemic lupus international collaborating Clinics\/American College of rheumatology (SLICC\/ACR) damage index for systemic lupus erythematosus international comparison","volume":"27","author":"Gladman","year":"2000","journal-title":"J Rheumatol"},{"key":"2025091512012723000_7.1.e000375.50","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cyto.2018.06.009","article-title":"Effect of storage duration on cytokine stability in human serum and plasma","volume":"113","author":"Vincent","year":"2019","journal-title":"Cytokine"},{"key":"2025091512012723000_7.1.e000375.51","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1002\/cti2.1047","article-title":"Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus","volume":"8","author":"Vincent","year":"2019","journal-title":"Clin Transl Immunology"},{"key":"2025091512012723000_7.1.e000375.52","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03219.x"},{"key":"2025091512012723000_7.1.e000375.53","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313496302"},{"key":"2025091512012723000_7.1.e000375.54","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1023\/A:1016040925295","article-title":"Serum sFAS levels are elevated in ANCA-positive vasculitis compared with other autoimmune diseases","volume":"22","author":"Christensson","year":"2002","journal-title":"J Clin Immunol"},{"key":"2025091512012723000_7.1.e000375.55","first-page":"60","article-title":"Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse","volume":"26","author":"van Lopik","year":"1999","journal-title":"J Rheumatol"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2019-000375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:01:35Z","timestamp":1757962895000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2019-000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,6,15]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1136\/lupus-2019-000375"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2019-000375","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}